Cooper Companies Inc (COO) Q1 2026 Earnings Call Transcript

Why It Matters

The results underscore Cooper’s successful rebound from pandemic lows and its expanding foothold in high‑margin vision and fertility markets, positioning the firm for sustained growth. Robust cash generation and strategic acquisitions enhance its competitive edge and long‑term profitability.

Key Takeaways

• Record Q2 revenue $720M, 37% YoY growth.
• CooperVision up 25%; CooperSurgical up 58%.
• Myopia management sales jumped 122% to $14M.
• Fertility revenue rose 53% to $84M.
• Free cash flow $143M; leverage down to 1.8x.

Pulse Analysis

Cooper Companies’ Q2 performance highlights a decisive rebound in the contact‑lens market, where silicone hydrogel daily lenses are gaining traction over older hydrogel products. The launch of MyDay, Clariti and expanded Biofinity toric options has helped CooperVision capture share across the Americas, EMEA and Asia‑Pac, driving a 31% surge in silicone hydrogel dailies. This momentum is amplified by a growing consumer focus on digital eye strain, positioning the firm to benefit from a market transition estimated at $2.4 billion in legacy daily lens upgrades.

Beyond lenses, Cooper’s myopia‑management portfolio exploded, with MiSight sales up 152% and ortho‑k revenue climbing 112%, pushing the segment to $14 million. The company’s broader fertility business also posted a 53% revenue jump to $84 million, while PARAGARD’s 103% growth underscores demand for hormone‑free contraceptives. These product‑level gains are reinforced by strategic acquisitions—No7 Contact Lens and OBP Medical—that deepen CooperVision’s specialty lens capabilities and CooperSurgical’s women’s‑health device suite, respectively, creating cross‑selling opportunities and expanding the addressable market.

Financially, Cooper delivered a 2.3‑point gross‑margin lift to 68.1% and an operating‑margin surge to 26.8%, reflecting higher‑margin surgical and fertility sales and disciplined expense management. Free cash flow of $143 million and a reduced net‑debt ratio of 1.8× provide ample liquidity for continued cap‑ex and R&D investment. The firm’s FY2021 outlook—revenues near $2.87 billion, EPS $13.30, and free cash flow exceeding $500 million—signals confidence in sustained demand, vaccine‑driven consumer recovery, and the long‑term macro trend of rising global myopia prevalence.